Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Madrigal Pharmaceuticals, Inc. (MDGL : NSDQ)
 
 • Company Description   
Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.

Number of Employees: 528

 
 • Price / Volume Information   
Yesterday's Closing Price: $582.34 Daily Weekly Monthly
20 Day Moving Average: 251,674 shares
Shares Outstanding: 22.71 (millions)
Market Capitalization: $13,225.77 (millions)
Beta: -1.00
52 Week High: $615.00
52 Week Low: $265.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.66% -0.49%
12 Week 35.97% 33.77%
Year To Date 0.00% 0.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 BARR HARBOR DRIVE SUITE 200
-
WEST CONSHOHOCKEN,PA 19428
USA		 ph: 267-824-2827
fax: 781-274-8228		 ir@madrigalpharma.com http://www.madrigalpharma.com
 
 • General Corporate Information   
Officers
William J. Sibold - President and Chief Executive Officer
Julian C. Baker - Chair of the Board
Mardi C. Dier - Chief Financial Officer
Rebecca Taub - Director
Fred B. Craves - Director

Peer Information
Madrigal Pharmaceuticals, Inc. (GSAC)
Madrigal Pharmaceuticals, Inc. (CASI)
Madrigal Pharmaceuticals, Inc. (ALCD.)
Madrigal Pharmaceuticals, Inc. (OMNN)
Madrigal Pharmaceuticals, Inc. (CGPI.)
Madrigal Pharmaceuticals, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 558868105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/25/26
Share - Related Items
Shares Outstanding: 22.71
Most Recent Split Date: 7.00 (0.03:1)
Beta: -1.00
Market Capitalization: $13,225.77 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $3.02 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 46.54% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/25/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 192.69
Trailing 12 Months: -
PEG Ratio: 4.14
Price Ratios
Price/Book: 21.14
Price/Cash Flow: -
Price / Sales: 17.86
EPS Growth
vs. Year Ago Period: -3.25%
vs. Previous Quarter: -167.37%
Sales Growth
vs. Year Ago Period: 362.03%
vs. Previous Quarter: 34.99%
ROE
12/31/25 - -
09/30/25 - -41.50
06/30/25 - -38.38
ROA
12/31/25 - -
09/30/25 - -26.18
06/30/25 - -27.32
Current Ratio
12/31/25 - -
09/30/25 - 3.44
06/30/25 - 5.11
Quick Ratio
12/31/25 - -
09/30/25 - 3.26
06/30/25 - 4.78
Operating Margin
12/31/25 - -
09/30/25 - -39.04
06/30/25 - -54.68
Net Margin
12/31/25 - -
09/30/25 - -39.04
06/30/25 - -54.68
Pre-Tax Margin
12/31/25 - -
09/30/25 - -39.04
06/30/25 - -54.68
Book Value
12/31/25 - -
09/30/25 - 27.55
06/30/25 - 31.35
Inventory Turnover
12/31/25 - -
09/30/25 - 0.63
06/30/25 - 0.47
Debt-to-Equity
12/31/25 - -
09/30/25 - 0.54
06/30/25 - 0.17
Debt-to-Capital
12/31/25 - -
09/30/25 - 35.19
06/30/25 - 14.54
 

Powered by Zacks Investment Research ©